Hjem › Hypofarynxcancer › Michigan
Kliniske studier for Hypofarynxcancer i Michigan
5 studier for Hypofarynxcancer søker deltakere på steder i Michigan.
Byer i Michigan
- Lansing4 studier
- Flint4 studier
- Waterford4 studier
- Ann Arbor3 studier
- Detroit3 studier
- Livonia3 studier
- Canton3 studier
Offisiell studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- og 8 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- og 23 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- og 60 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- McLaren Cancer Institute-Bay City, Bay City
- McLaren Cancer Institute-Clarkston, Clarkston
- Wayne State University/Karmanos Cancer Institute, Detroit
- og 8 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06532279Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT04198766Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.